CRANBURY, N.J., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases, today announced that an oral presentation and 3 posters related to its investigational pharmacological chaperones will be included at two upcoming scientific meetings.
October 30-November 4, 2012 in San Diego, CA
Long Term Effects of Migalastat HCl on Fabry Nephropathy. - Germain D.P., Giugliani R., Pastores G., Nicholls K., Shankar S., Schiffmann R., Hughes D., Mehta A., Waldek S., Jovanovic A., Bragat A., Sitaraman S., Sniukiene V., Winkler R., Boudes P.
- Oral Abstract Session: Saturday, November 3, 2012, 4:30-6:30pm PDT (Dominique P. Germain, U. of Versailles)
November 6-10, 2012 in San Francisco, CA
Long-Term Safety of Migalastat HCl in Patients with Fabry Disease. – Germain D.P., Giugliani R., Pastores G., Nicholls K., Shankar S., Schiffmann R., Hughes D., Mehta A., Waldek S., Jovanovic A., Benistan K., Simosky J., Sniukiene V., Winkler R., Boudes P.
- Poster: November 7, 2012, 3:15-4:15 pm PST (Dominique P. Germain, U. of Versailles)
A Phase 2a Study to Investigate the Effects of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Alpha-Gal A Activity in Subjects with Fabry Disease. – Johnson F., Mudd Jr. P., Sitaraman S., Winkler R., Flanagan J., Khanna R., Valenzano K., Lockhart D., Boudes P. On Behalf of Study AT1001-013 Principal Investigators
- Poster: November 8, 2012, 3:15-4:15 pm PST (David Warnock, U. of Alabama-Birmingham)
High Incidence of GLA Variants in a Non-Selected Heart Disease Patient Population Suggests that the Fabry Trait is a Common Cardiovascular Genetic Risk Factor. - Schiffmann R., Forni S., Swift C., Wu X.,Lockhart D., Chee M., Kitaoka T., Chudin E., Pond S., McNeill N., Sims K., Benjamin E., Sweetman L.
- Poster: November 8, 2012, 3:15-4:15 pm PST (Raphael Schiffmann, Baylor Research Institute)
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company is developing orally-administered, small molecule drugs called pharmacological chaperones, a novel, first-in-class approach to treating a broad range of human genetic diseases. Amicus' late-stage programs for lysosomal storage disorders include migalastat HCl monotherapy in Phase 3 for Fabry disease; migalastat HCl co-administered with enzyme replacement therapy (ERT) in Phase 2 for Fabry disease; and AT2220 co-administered with ERT in Phase 2 for Pompe disease.
CONTACT: Investors/Media: Sara Pellegrino email@example.com (609) 662-5044Source:Amicus Therapeutics, Inc.